ITI MF

CATEGORY OF SCHEME	Sectoral/Thematic
INVESTMENT OBJECTIVE	The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. However, there can be no assurance that the investment objective of the scheme would be achieved.
Inception Date (Date of Allotment):	08-Nov-21
Benchmark:	Nifty Healthcare TRI
Minimum Application Amount:	Rs.5,000/- and in multiples of Rs. 1/- thereafter
Load Structure:	Entry Load: Nil Exit Load: 1% if redeemed or switched out on or before completion of 12 months from the date of allotment of units · Nil, if redeemed or switched out after completion of 12 months from the date of allotment of units.
Total Expense Ratio (TER):	Including Additional Expenses and Goods and Service Tax on Management Fees Regular Plan: 2.34% Direct Plan: 0.43%
Fund Manager	Mr. Rohan Korde (Since 08-Nov-21) Total Experience: 19 years Mr. Dhimant Shah (Since 01 December 2022) Total Experience : 26 years

AUM (in Rs. Cr):	143.28
AAUM (in Rs. Cr):	140.13
% of top 5 holdings:	35.94 %
% of top 10 holdings:	59.19%
No. of scrips:	35

Standard Deviation^:	NA
Beta^:	NA
*Sharpe Ratio^:**	NA
Average P/B	6.95
Average P/E	103.53
Portfolio Beta	0.82
^Scheme has not completed 3 years hence NA * Risk free rate:6.90 (Source: FIMMDA MIBOR)

	Regular Plan (in Rs.)	Direct Plan (in Rs.)
Growth:	12.3386	12.9183
IDCW:	12.3386	12.9183

Name of the Instrument	% to NAV	% to NAV Derivatives
Equity & Equity Related Total	97.76
Chemicals	4.34
Vishnu Chemicals Limited	1.72
Archean Chemical Industries Limited	1.72
Astec LifeSciences Limited	0.90
Healthcare	93.41
Sun Pharmaceutical Industries Limited	13.58
Dr. Reddy's Laboratories Limited	5.92
Max Healthcare Institute Limited	5.89
Alkem Laboratories Limited	5.38
Suven Pharmaceuticals Limited	5.16
Mankind Pharma Limited	4.96
Aurobindo Pharma Limited	4.92
Lupin Limited	4.58
Cipla Limited	4.56
Apollo Hospitals Enterprise Limited	4.23
Laurus Labs Limited	3.63
Divi's Laboratories Limited	3.52
Zydus Lifesciences Limited	2.96
JB Chemicals & Pharmaceuticals Limited	2.13
FDC Limited	1.93
Alembic Pharmaceuticals Limited	1.90
Syngene International Limited	1.84
Orchid Pharma Limited	1.49
Piramal Pharma Limited	1.42
Vijaya Diagnostic Centre Limited	1.37
Ajanta Pharma Limited	1.33
Sun Pharma Advanced Research Company Limited	1.17
Sanofi India Limited	1.10
Rainbow Childrens Medicare Limited	1.06
Fortis Healthcare Limited	1.05
IPCA Laboratories Limited	0.99
Narayana Hrudayalaya Limited	0.99
Abbott India Limited	0.93
Sequent Scientific Limited	0.92
GlaxoSmithKline Pharmaceuticals Limited	0.86
Dr. Lal Path Labs Limited	0.82
Healthcare Global Enterprises Limited	0.82
Short Term Debt & Net Current Assets	2.24

Top Ten Holdings

Period	Fund Returns (%)	Benchmark Returns (%)	Additional Benchmark Returns (%)	Benchmark (Rs)	Fund (Rs)	Additional Benchmark Returns (Rs)
Regular - Growth
Last 1 Year	31.7%	34.1%	21.4%	13,161	13,399	12,130
Since Inception	10.3%	11.0%	10.3%	12,339	12,512	12,323
Direct - Growth
Last 1 Year	34.5%	34.1%	21.4%	13,439	13,399	12,130
Since Inception	12.7%	11.0%	10.3%	12,918	12,512	12,323

Past performance may or may not be sustained in future and is not a guarantee of any future returns, and should not be used as a basis of comparison with other investments. The performance data for 3 years period has not been provided, since scheme is in existence for less than 3 years. In case, the start / end date of the concerned period is a non-business date (NBD), the NAV of the previous date is considered for computation of returns. Different Plans i.e. Regular Plan and Direct Plan under the scheme have different expense structure. Benchmark: Nifty Healthcare TRI Additional Benchmark: Nifty 50 TRI. Fund Managers: Mr. Rohan Korde (Managing since 08-Nov-21) and Mr. Dhimant Shah (Managing since 01-December-22). Inception date of the scheme is (08-Nov-2021). Face Value per unit: Rs. 10.

Period	Amount Invested	Fund Value ()	Fund Returns (%)	Benchmark Value ()	Benchmark Returns (%)	Additional Benchmark Value ()	Additional Benchmark Returns (%)
Regular - Growth
Last 1 Year	1,20,000	1,48,313	47.0%	1,48,930	48.1%	1,40,517	33.5%
Since Inception	2,60,000	3,31,070	23.2%	3,31,463	23.3%	3,19,461	19.6%
Direct - Growth
Last 1 Year	1,20,000	1,50,013	50.0%	1,48,930	48.1%	1,40,517	33.5%
Since Inception	2,60,000	3,39,040	25.7%	3,31,463	23.3%	3,19,461	19.6%

Past performance may or may not be sustained in future. Different Plans i.e. Regular Plan and Direct Plan under the scheme have different expense structure. Benchmark: Nifty Healthcare TRI Additional Benchmark: Nifty 50 TRI. For SIP returns, monthly investment of Rs.10,000 invested on the 1st business day of every month has been considered. CAGR Returns (%) are computed after accounting for the cash flow by using the XIRR method (investment internal rate of return).